Therapies directed at vascular endothelial growth factor.
about
Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.New insights in synovial angiogenesis.Angiogenesis in rheumatoid arthritis.A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy.Malignant pleural mesothelioma--an update.Colon cancer angiogenesis and antiangiogenic therapy.Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activityAge-related maculopathy in the light of ischaemia.Potential therapeutic strategies for lymphatic metastasis.New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity.Bevacizumab in the therapy for refractory metastatic colorectal cancer.Bevacizumab in the treatment of HER2-negative breast cancer.Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism.Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis.Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures.Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.Ten years of anti-vascular endothelial growth factor therapy.Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.The pigment epithelium-derived factor (PEDF): an important potential therapeutic agent for infantile hemangioma.Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.
P2860
Q24810669-7865B0F5-458B-4FC3-8467-DCEFF0487733Q31139165-27792849-2ACD-4D42-945B-83D19B903B23Q34022062-E9A87284-7C45-40DD-AA8F-FB90892A7936Q34051829-7C7FD40E-AFE6-4684-8A1A-26306D2EF28CQ34851156-C163418C-78B6-43AA-B02E-8EF2DC545324Q35204961-64F51032-D0BB-456F-BDAA-AFE933EF4880Q35740408-8618D616-152E-4D67-863B-32AEA4800066Q35790787-00764491-2D04-4BF8-870F-1EE35DFD7B8AQ35836870-DF7FB4AE-D722-495B-AD9E-8F84652E0F3EQ36146888-A853EFE3-5BC1-42E4-9006-B207CB373003Q36834429-580A2E6E-2098-439D-9DD1-BD66F3A29013Q36851512-C2D198D2-15AD-4743-A8BC-4FFDA63D88A9Q36879172-E98678EE-02F7-46C6-9868-B645C871A1A9Q37247262-8E6BD9EE-9A83-47EC-8406-BFAECA0AC364Q37307590-5BD061ED-2D58-41FC-A0DC-B7E5DCE1C8D5Q37307819-C1A5BA78-23DD-4A9D-96B3-1DB3B786264BQ37451272-F41069C0-DADB-4473-A5B4-2F63BBF2A782Q37594844-520809EA-9B6D-4C9F-9AD3-3EB9D81B9431Q38184546-1CEC6ACD-6420-46F3-A64E-632F664480B0Q39303918-20BFB2A9-4D4A-4D48-BE3F-2F91B873B05BQ43168867-89E99ECB-FFFA-45D0-8C10-12D2FAAD768CQ44830447-7F13428E-E1F7-45D6-91E1-27B87BB82F12Q46407140-2DF404E4-9053-4F3D-AB49-9CBC355033A2Q50886676-915C015F-2991-4547-B2AE-6675F104F1EEQ51137674-C462475E-9C80-4B1E-A8B6-3F66718A4339Q54515089-0F4BC0C7-5D26-4B6D-81F9-1C2DA9E4FCB6Q55476332-2FD5A501-F466-4CD2-9628-D6A249E6C062
P2860
Therapies directed at vascular endothelial growth factor.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Therapies directed at vascular endothelial growth factor.
@ast
Therapies directed at vascular endothelial growth factor.
@en
type
label
Therapies directed at vascular endothelial growth factor.
@ast
Therapies directed at vascular endothelial growth factor.
@en
prefLabel
Therapies directed at vascular endothelial growth factor.
@ast
Therapies directed at vascular endothelial growth factor.
@en
P2093
P2860
P1476
Therapies directed at vascular endothelial growth factor.
@en
P2093
Georg Martiny-Baron
Jean-Marc Schlaeppi
Jeanette M Wood
Paul W Manley
P2860
P304
P356
10.1517/13543784.11.12.1715
P407
P577
2002-12-01T00:00:00Z